daridorexant 50 MG Oral Tablet [Quviviq]
daridorexant
RxCUI: 2599098
What the CMS Formulary Data Shows for daridorexant 50 MG Oral Tablet [Quviviq]
Per the CMS 2026 Part D formulary file, daridorexant 50 MG Oral Tablet [Quviviq] (RxNorm concept RXCUI 2599098, generic name daridorexant) appears on 4 distinct formulary files spanning 775 Medicare Part D plan offerings - 15.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.
Real-world access to daridorexant 50 MG Oral Tablet [Quviviq] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 10,838 Part D beneficiaries filled daridorexant 50 MG Oral Tablet [Quviviq] in 2023, with total plan-and-beneficiary spending of $16,342,719 and an average per-beneficiary annual cost of $1,507.91. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry daridorexant 50 MG Oral Tablet [Quviviq] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 775
- Coverage rate
- 15.3%
- Tier range
- Tier 4, Non-Preferred
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 10,838
- Total spending
- $16,342,719
- Avg per beneficiary
- $1,507.91
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering daridorexant 50 MG Oral Tablet [Quviviq]
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering daridorexant 50 MG Oral Tablet [Quviviq]
98 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is daridorexant 50 MG Oral Tablet [Quviviq] covered by Medicare Part D?
Yes, daridorexant 50 MG Oral Tablet [Quviviq] is covered by 775 Medicare Part D plans (15.3% of all Part D formularies).
What tier is daridorexant 50 MG Oral Tablet [Quviviq] on Medicare Part D plans?
daridorexant 50 MG Oral Tablet [Quviviq] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.
Does daridorexant 50 MG Oral Tablet [Quviviq] require prior authorization?
0% of Part D formularies require prior authorization for daridorexant 50 MG Oral Tablet [Quviviq]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on daridorexant 50 MG Oral Tablet [Quviviq]?
In 2023, total Medicare Part D spending on daridorexant 50 MG Oral Tablet [Quviviq] was $16,342,719, covering 10,838 beneficiaries. The average spend per beneficiary was $1,507.91.
Read our methodology - how this data is sourced, computed, and verified.